Investment analysts at Cantor Fitzgerald initiated coverage on shares of Aimmune Therapeutics (NASDAQ:AIMT) in a research note issued on Sunday. The brokerage set a “buy” rating and a $64.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 169.47% from the company’s previous close.
The analysts wrote, “. We are assuming coverage of AIMT with an Overweight rating and a 12-month PT of $64 based on lead asset AR101 in peanut allergy. Given the growing unmet clinical need in PA, ‘101 has Track designations, and we believe a high regulatory PoS exists based on data from the P3 PALISADE study. Full study data were recently published in the NEJM, validating the results and further enhancing our conviction given the notably reduced use of rescue epinephrine during the DBPCFC and limited use during updosing.””
A number of other equities research analysts also recently commented on the company. Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, November 19th. Roth Capital set a $80.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, November 19th. Wedbush set a $80.00 target price on Aimmune Therapeutics and gave the company a “buy” rating in a research report on Monday, November 12th. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 12th. Finally, Stifel Nicolaus set a $33.00 target price on Aimmune Therapeutics and gave the company a “hold” rating in a research report on Sunday, November 11th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $51.70.
NASDAQ:AIMT traded up $0.10 on Friday, reaching $23.75. The company’s stock had a trading volume of 787,472 shares, compared to its average volume of 817,101. Aimmune Therapeutics has a 12-month low of $23.15 and a 12-month high of $42.00. The company has a market capitalization of $1.39 billion, a P/E ratio of -9.10 and a beta of -0.10.
Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.03. Equities analysts expect that Aimmune Therapeutics will post -3.65 EPS for the current year.
In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas bought 3,650 shares of Aimmune Therapeutics stock in a transaction on Monday, November 19th. The shares were bought at an average price of $27.56 per share, for a total transaction of $100,594.00. Following the completion of the transaction, the insider now directly owns 63,600 shares of the company’s stock, valued at $1,752,816. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 24.56% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Tiverton Asset Management LLC acquired a new stake in shares of Aimmune Therapeutics in the second quarter valued at $145,000. Ardsley Advisory Partners acquired a new stake in shares of Aimmune Therapeutics in the second quarter valued at $202,000. Atria Investments LLC acquired a new stake in shares of Aimmune Therapeutics in the third quarter valued at $213,000. Xact Kapitalforvaltning AB acquired a new stake in shares of Aimmune Therapeutics in the third quarter valued at $221,000. Finally, Rehmann Capital Advisory Group grew its stake in shares of Aimmune Therapeutics by 2,242.4% in the third quarter. Rehmann Capital Advisory Group now owns 6,465 shares of the biotechnology company’s stock valued at $237,000 after buying an additional 6,189 shares in the last quarter. 76.92% of the stock is owned by institutional investors and hedge funds.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
Featured Story: What is Compound Interest?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.